Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2025)

ARS Pharmaceuticals' Assets Average history spans 5 years, with the latest figure at $350.2 million for Q4 2025.

  • For Q4 2025, Assets Average rose 23.16% year-over-year to $350.2 million; the TTM value through Dec 2025 reached $350.2 million, up 23.16%, while the annual FY2025 figure was $339.4 million, 16.17% up from the prior year.
  • Assets Average for Q4 2025 was $350.2 million at ARS Pharmaceuticals, up from $343.1 million in the prior quarter.
  • Across five years, Assets Average topped out at $374.6 million in Q2 2021 and bottomed at $187.0 million in Q1 2022.
  • The 5-year median for Assets Average is $276.3 million (2023), against an average of $281.0 million.
  • The largest annual shift saw Assets Average dropped 21.47% in 2022 before it surged 56.13% in 2025.
  • A 5-year view of Assets Average shows it stood at $207.0 million in 2021, then soared by 33.45% to $276.2 million in 2022, then decreased by 12.81% to $240.9 million in 2023, then rose by 18.06% to $284.4 million in 2024, then grew by 23.16% to $350.2 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Assets Average are $350.2 million (Q4 2025), $343.1 million (Q3 2025), and $320.4 million (Q2 2025).